Coya Therapeutics (NASDAQ:COYA) Earns “Buy” Rating from D. Boral Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $15.00 price target on the stock. D. Boral Capital’s price target suggests a potential upside of 119.62% from the company’s current price.

COYA has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research report on Monday, November 11th. Chardan Capital reissued a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday, November 7th.

Coya Therapeutics Price Performance

COYA opened at $6.83 on Thursday. The company has a market capitalization of $114.13 million, a price-to-earnings ratio of -10.51 and a beta of 0.47. The business’s 50-day moving average price is $5.87 and its two-hundred day moving average price is $6.40. Coya Therapeutics has a 1 year low of $4.75 and a 1 year high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.15. Sell-side analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Arun Swaminathan acquired 5,000 shares of the stock in a transaction on Monday, November 11th. The shares were purchased at an average price of $7.34 per share, for a total transaction of $36,700.00. Following the purchase, the chief executive officer now directly owns 5,000 shares in the company, valued at approximately $36,700. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders purchased 9,510 shares of company stock worth $69,615 over the last three months. Insiders own 9.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new stake in shares of Coya Therapeutics in the 2nd quarter valued at $101,000. GHP Investment Advisors Inc. acquired a new position in Coya Therapeutics during the third quarter worth about $169,000. Geode Capital Management LLC lifted its stake in Coya Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after purchasing an additional 4,485 shares during the last quarter. Newbridge Financial Services Group Inc. bought a new position in shares of Coya Therapeutics in the 4th quarter valued at $401,000. Finally, CM Management LLC boosted its position in Coya Therapeutics by 11.1% during the 4th quarter. CM Management LLC now owns 160,000 shares of the company’s stock worth $917,000 after buying an additional 15,941 shares during the period. 39.75% of the stock is owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.